
Lauren Simonetti reports on Eli Lilly's stock reaching a new record high, surpassing $1,000 per share. This surge is attributed to the success of its obesity drug portfolio, including Mounjaro and Zepbound, with analysts predicting a further increase to $1,182 as the company is expected to reach 18 million people and generate $101 billion in peak revenue.